Use of gp130 activators in diabetic neuropathy

Details Use of gp130 activators in diabetic neuropathy Use of gp130 activators in diabetic neuropathy

2002-10-10

2008-12-16

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C424S085100, C514S012200

Reexamination Certificate

active

07465441

ABSTRACT:
The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.

REFERENCES:
patent: 6054294 (2000-04-01), Chang
patent: 6479258 (2002-11-01), Short
patent: WO 95/00852 (1995-01-01), None
patent: WO 96/27672 (1996-09-01), None
patent: WO 01/03737 (2001-01-01), None
Müller-Newen, G. (2003). The cytokine receptor gp130: faithfully promiscuous. Science's STKE. PE40:1-3.
Wells, J.A. (1990). Additivity of mutational effects in proteins. Biochemistry. 29(37):8509-8517.
Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491-495.
Skolnick et al. (2000). From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology. 18:34-39.
Vincent et al. (2004). New insights into the mechanisms of diabetic neuropathy. Reviews in Endocrine and Metabolic Disorders. 5:227-236.
Phillips, A.J. (2001). The challenge of gene therapy and DNA delivery. Journal of Pharmacy and Pharmacology. 53:1169-1174.
Palù et al. (1999). In pursuit of new developments for gene therapy. Journal of Biotechnology. 68:1-13.
Senaldi et al. (1999). Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc. Natl. Acad. Sci. USA. 96(20):11458-11463.
Federico, M. “Lentiviruses as gene delivery vectors”Current Opinion in Biotechnology10 pp. 448-453 (1999).
Loddick et al “Interleukin-1 receptors: cloning studies and role in central nervous system disorders”Brain Research Reviews26 pp. 306-319 (1998).
Ma et al “Neurotoxic Effects of Interleukin-6 and Sodium Nitroprusside on Cultured Rat Hippocampal Neurons”Arzneim.-Forsch./Drug Res. 50 (I), Nr. 6 pp. 512-514 (2000).
Pittenger et al “IL6 Blocks Neurotoxicity of Diabetic Neuropathy Patients' Sera on Neuropblastoma Cells”Diabetes, 48 pp. A384 (1998).
Schafer et al “The IL-6/IL-6R Fusion Protein Hyper IL-6 Promotes Neurite Outgrowth and Neuron Survival in Cultured Enteric Neurons”Journal of Interferon and Cytokine Research19 pp. 527-532. (1999).
Takizawa et al “Directly Linked Soluble IL-6 Receptor-IL-6 Fusion Protein Induces Astrocyte Differenctiation From Neuropithelial Cells via Activation of STAT3”Cytokine, vol. 13, No. 5 (Mar. 7, 2001) pp. 272-279.
Van Wagoner et al “Interleukin-6 (IL-6) Production by Astrocytes: Autocrine Regulation by IL-6 and the Soluble IL-6 Receptor”The Journal of Neuroscience, 19(13) pp. 5236-5244 (1991).
Vinik A I et al “Diabetic Neuropathies”Diabetes Care, American Diabetes Association15(12): pp. 1926-1975 (1992).
Vinik et al “Neuroptrophic factors in diabetic neuropathy”Current Opinion in Endocrinology and Diabetes8(4), pp. 205-212 (2001).

Affiliated with

Also associated with

Rating

Use of gp130 activators in diabetic neuropathy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of gp130 activators in diabetic neuropathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of gp130 activators in diabetic neuropathy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4028328